Actively Recruiting
MATCHES-Novel: Making Telehealth Delivery of Cancer Care at Home Effective and Safe for Tarlatamab in Small Cell Lung Carcinoma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-27
70
Participants Needed
7
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether a Hospital-at-Home (HaH) program is a more efficient way to monitor health after receiving tarlatamab compared to monitoring in the hospital. This study focuses on people with extensive stage small cell lung carcinoma and aims to compare health outcomes and hospital stay lengths using different care delivery models. Participants are randomly assigned to one of two groups. One group receives tarlatamab treatment as usual in the hospital, while the other group receives tarlatamab through the hospital-at-home care model. In this model, after discharge, a community paramedic visits the participant's home to provide care and monitoring. This approach is designed to deliver treatment safely in a homebound setting within specific geographic areas. Throughout the study, researchers will track the number of inpatient hospital days within 14 days as the primary outcome. Participants will be monitored with regular visits and assessments to evaluate their health status. Caregivers are required to support participants in the hospital-at-home group, and the study includes safety monitoring and follow-up to ensure proper care during the treatment period. The overall participation period extends until April 2028.
CONDITIONS
Brief Title
A Study of Hospital-at-Home for People Receiving Tarlatamab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)
- Treatment plan includes commercially available tarlatamab monotherapy as standard care
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status less than 2
- Adequate organ and bone marrow function confirmed by laboratory results within 28 days before first treatment
- Willingness to provide and sign informed consent
- Appropriate homebound setting within specified geographic areas
- Availability of a caregiver during enrollment in the Hospital-at-Home program
You will not qualify if you...
- Documented active infection prior to starting tarlatamab, including grade 3 or higher viral, bacterial, or fungal infections
- Baseline dementia or cognitive barriers
- Uncontrolled arrhythmias
- Caregiver deemed inappropriate by treating physician
- No physician exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of tarlatamab treatment as per standard care
Participants receive tarlatamab administration either through usual care or via the hospital-at-home care delivery model.
Visits depend on treatment delivery method (hospital or home visits)
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
R
Robert Daly, MD, MBA
M
Michael Offin, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here